Prospective economic evaluation alongside the non-invasive ventilation trial

M. E. Mowitz, J. A.F. Zupancic, D. Millar, H. Kirpalani, J. S. Gaulton, R. S. Roberts, W. Mao, D. Dukhovny

Research output: Contribution to journalArticle

6 Scopus citations


Objective:To determine the cost-effectiveness of nasal continuous positive pressure (nCPAP) compared with nasal intermittent positive pressure ventilation (NIPPV) in the context of the reported randomized clinical trial.Study Design:Using patient-level data from the clinical trial, we undertook a prospectively planned economic evaluation. We measured costs, from a third-party payer perspective in all patients, and from a societal perspective in a subgroup with a time horizon through the earlier of discharge, death or 44 weeks post-menstrual age.Results:From the third-party payer perspective, the mean cost of hospitalization per infant was statistically similar, $143 745 in the NIPPV group compared to $140 403 in the nCPAP group. Cost-effectiveness evaluation revealed a 61% probability that NIPPV is more expensive and less effective than nCPAP. Similar results were found in subgroup analysis from a societal perspective.Conclusion:In addition to being clinically equivalent, economic evaluation confirms that NIPPV, as employed in this trial, is also not economically favorable.

Original languageEnglish (US)
Pages (from-to)61-66
Number of pages6
JournalJournal of Perinatology
Issue number1
StatePublished - Jan 1 2017

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Prospective economic evaluation alongside the non-invasive ventilation trial'. Together they form a unique fingerprint.

  • Cite this

    Mowitz, M. E., Zupancic, J. A. F., Millar, D., Kirpalani, H., Gaulton, J. S., Roberts, R. S., Mao, W., & Dukhovny, D. (2017). Prospective economic evaluation alongside the non-invasive ventilation trial. Journal of Perinatology, 37(1), 61-66.